Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-01-01
2008-01-01
Tsang, Cecilia J. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200
Reexamination Certificate
active
07314859
ABSTRACT:
Pharmaceutical composition comprising both insulin and glucagon can be administered to control and treat diabetes while reducing or eliminating the risk of insulin-induced hypoglycemia.
REFERENCES:
patent: 2902408 (1959-09-01), Bouman et al.
patent: 3897551 (1975-07-01), Bromer
patent: 4003379 (1977-01-01), Ellinwood, Jr.
patent: 4492684 (1985-01-01), Goosen et al.
patent: 4498843 (1985-02-01), Schneider et al.
patent: 4538616 (1985-09-01), Rogoff
patent: 4633878 (1987-01-01), Bombardieri
patent: 4826763 (1989-05-01), Norris et al.
patent: 4839174 (1989-06-01), Baker et al.
patent: 4943435 (1990-07-01), Baker et al.
patent: 5101814 (1992-04-01), Palti
patent: 5190041 (1993-03-01), Palti
patent: 5234903 (1993-08-01), Nho et al.
patent: 5234906 (1993-08-01), Young et al.
patent: 5237993 (1993-08-01), Skrabal
patent: 5321008 (1994-06-01), Beaumont et al.
patent: 5359030 (1994-10-01), Ekwuribe
patent: 5445832 (1995-08-01), Orsolini et al.
patent: 5474552 (1995-12-01), Palti
patent: 5508260 (1996-04-01), Beaumont et al.
patent: 5527771 (1996-06-01), Beaumont et al.
patent: 5542935 (1996-08-01), Unger et al.
patent: 5637568 (1997-06-01), Orsolini et al.
patent: 5643604 (1997-07-01), Angeles Uribe et al.
patent: 5643607 (1997-07-01), Okada et al.
patent: 5656590 (1997-08-01), Rink et al.
patent: 5707641 (1998-01-01), Gertner et al.
patent: 5741211 (1998-04-01), Renirie et al.
patent: 5814600 (1998-09-01), Rink et al.
patent: 5849322 (1998-12-01), Ebert et al.
patent: 5869602 (1999-02-01), Jonassen et al.
patent: 5919216 (1999-07-01), Houben et al.
patent: 6093167 (2000-07-01), Houben et al.
patent: 6103233 (2000-08-01), Pouletty et al.
patent: 6107489 (2000-08-01), Krantz et al.
patent: 6114304 (2000-09-01), Kolterman et al.
patent: 6135978 (2000-10-01), Houben et al.
patent: 6191105 (2001-02-01), Ekwuribe et al.
patent: 6197333 (2001-03-01), Onyuksel et al.
patent: 6217893 (2001-04-01), Pellet et al.
patent: 6239107 (2001-05-01), Gozes et al.
patent: 6261280 (2001-07-01), Houben et al.
patent: 6277863 (2001-08-01), Krantz et al.
patent: 6284727 (2001-09-01), Kim et al.
patent: 6319510 (2001-11-01), Yates
patent: 6329336 (2001-12-01), Bridon et al.
patent: 6348214 (2002-02-01), Onyuksel et al.
patent: 6461331 (2002-10-01), Van Antwerp
patent: 6500918 (2002-12-01), Ezrin et al.
patent: 6520326 (2003-02-01), McIvor et al.
patent: 6559122 (2003-05-01), Oeswein et al.
patent: 6566490 (2003-05-01), Maniqub et al.
patent: 6572542 (2003-06-01), Houben et al.
patent: 6573238 (2003-06-01), Shirley et al.
patent: 6589548 (2003-07-01), Oh et al.
patent: 6593295 (2003-07-01), Bridon et al.
patent: 6703365 (2004-03-01), Galloway et al.
patent: 2001/0016643 (2001-08-01), Jonassen et al.
patent: 2001/0033858 (2001-10-01), Zhang
patent: 2002/0026141 (2002-02-01), Houben et al.
patent: 2002/0114829 (2002-08-01), Onyuksef et al.
patent: 2002/0115592 (2002-08-01), New et al.
patent: 2002/0119146 (2002-08-01), Dupre
patent: 2003/0108568 (2003-06-01), Bridon et al.
patent: 2004/0110817 (2004-06-01), Hulin
patent: 0 300 552 (1989-01-01), None
patent: 0442724 (1991-08-01), None
patent: 0684044 (1995-11-01), None
patent: 0816381 (1998-01-01), None
patent: 1264837 (2002-12-01), None
patent: 748857 (1956-05-01), None
patent: 766994 (1957-01-01), None
patent: 766995 (1957-01-01), None
patent: 831907 (1960-04-01), None
patent: 844434 (1960-08-01), None
patent: WO 8809341 (1988-12-01), None
patent: WO 9703688 (1988-12-01), None
patent: WO 9724440 (1997-07-01), None
patent: WO 9808871 (1998-03-01), None
patent: WO 9831383 (1998-07-01), None
patent: WO 9943708 (1999-09-01), None
patent: WO 01/54742 (2001-08-01), None
patent: WO 0182981 (2001-11-01), None
patent: WO 0222154 (2002-03-01), None
patent: WO 0232957 (2002-04-01), None
patent: WO 02/43566 (2002-06-01), None
patent: WO 0246227 (2002-06-01), None
patent: WO 04060387 (2004-07-01), None
patent: WO 0182874 (2004-11-01), None
Trading et al. Europ. J. of Pharm. 7 (1969) 206-210 (also cited in IDS of Mar. 20, 2006).
Bremer et al. Protein Delivery with Infusion Pumps. Ch. 9, cited in Protein Delivery-Physical Systems, 1997, Plenum Press, pp. 248-249 (also cited in Applicant's IDS of Mar. 20, 2006).
Houlbert et al. “Continuois Subcutaneous Infusion of Glucagon by Portable Pump in Non Beta Cell Tumor Hypoglycemia,” Diabete & Metab. 11 (2): 125-7, Apr. 1985); IDS, May 2, 2007).
Abs et al., “Hypoglycemia owing to inappropriate glucagons secretion treated with a continuous subcutaneous glucagons infusion system,”Acta Endocrinol(Copenh), 122(3):319-322 (1990).
Atvall et al., “Insulin-antagonistic effects of pulsatile and continuous glucagons infusions in man—a comparison with the effect of adrenaline,”J. Clin Endocrinol. Metab., 74(5):1110-1115 (1992).
Aynsley-Green et al., “Nesidioblastosis of the pancreas: definition of the syndrome and the management of the severe neonatal hyperinsulinaemic hypoglycaemia,”Arch. Dis. Child., 56(7):496-508 (1981).
Bergman et al., “Central role of the adipocyte in the metabolic syndrome,”J. Investig. Med., 49(1):119-126 (2001).
Bolli et al., “Nocturnal blood glucose control in type I diabetes mellitus,”Diabetes Care, 16(suppl. 3):71-89 (1993).
Bratusch-Marrian et al., “The role of ‘diabetogenic’ hormones on carbohydrate and lipid metabolism following oral glucose laoding in insulin dependent diabetics: effect of acute hormone administration,”Diabetologia, 21(4):387-393 (1981).
Bray, G.A., “The Zucker-fatty rat: a review,”Fed. Proc., 36(2):148-153 (1977).
Bremer et al., “Protein delivery with infusion pumps,”Pharm. Biotechnol., 10:239-254 (1997).
Cederblad et al., “Effect of glucagons on glucose production, lipolysis, and gluconeogenesis in familial hyperinsulinism,”Horm. Res., 50(2):94-98 (1998).
Christiansen et al., “Zinc-protamine-glucagon in the treatment of Paget's disease of bone. Preliminary Report,”Acta Med. Scand., 196(6):495-496 (1974).
Clarke et al., “The effect of hyperglucagonemia on blood glucose concentrations and on insulin requirements in insulin-requiring diabetes mellitus,”Diabetes, 27(6):649-652 (1978).
Cryer et al., “Hypoglycemia in Diabetes,”Diabetes Care, 26(6):1902-1912 (2003).
Day et al., “Depot-glucagon in the treatment of McArdle's disease,”Aust N.Z. J. Med., 15(6):748-750 (1985).
Haymond et al., “Mini-Dose Glucagon Rescue for Hypoglycemia in children With Type 1 Diabetes,”Diabetes Care, 24(4):643-645 (2001).
Ivkovic-Lazar, T., “Development and differentiation of adipose tissue,”Med. Pregl., 56(3-4):142-145 (2003), abstract, article in Croatian.
Kalima et al., “The effect of zinc-protamine-glucagon in acute pancreatitis,”Ann. Chir. Gynaecol., 69(6):293-295 (1980).
Kollee et al., “Persistent neonatal hypoglycaemia due to glucagons deficiency,”Arch Dis. Child, 53(5):422-424 (1978).
Nicolaidis, S., “Physiology of food intake and regulation of body weight,”Ann. Endocrinol., 49(2):89-97 (1988) abstract, article in French.
Pichler et al., “Haemodynamic effects of depot zinc protamine glucagons in heart failure,”Wein Klin Wochenschr., 91(2):49-51 (1979) abstract only, article in German.
Schmid et al., “McArdle's disease: therapeutic use of depot-glucagon,”Dtsch Med. Wochenschr., 107(47):1809-1811 (1982) abstract only, article in German.
Trading et al., “Bioogical and Chemical Properties of Two Glucagon Preparations with Prolonged Action,”Eur. J. Pharmacology, 7:206-210 (1969).
Edelman, “Nocturnal Administration of Very Low Dose Glucagon in Patients with Type 1 Diabetes Reduces Episodes of Nocturnal Hypoglycemia,” PowerPoint Presentation at ADA 67th Scientific Sessions, Jun. 22, 2007.
Banarer et al., “Intraislet Hyperinsulinemia Prevents the Glucagon Response to Hypoglycemia Despite an Intact Autonomic Response,”Diabetes, 51:958-965.
Bolli et al., “Abnorm
Green Daniel T
Henry Robert R.
Audet Maury
DiObex, Inc.
Townsend and Townsend / and Crew LLP
Tsang Cecilia J.
LandOfFree
Compositions and methods for the prevention and control of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for the prevention and control of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the prevention and control of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2813669